Compare
Immunic, Inc. vs Kiora Pharmaceuticals Inc vs HCW Biologics Inc. vs Integrated Biopharma Inc
| Latest fiscal year | Immunic, Inc. IMUX | Kiora Pharmaceuticals Inc KPRX | HCW Biologics Inc. HCWB | Integrated Biopharma Inc INBP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-06-30 |
| Revenue | n/a | $0 | $54.2K | $54.35M |
| Revenue growth (YoY) | n/a | -100.0% | -97.9% | +8.0% |
| Gross margin | n/a | n/a | 20.0% | 10.2% |
| Operating margin | n/a | n/a | n/m | 3.7% |
| Net margin | n/a | n/a | n/m | 1.5% |
| Net income | -$97.17M | -$10.84M | -$7.96M | $808.0K |
| EPS (Diluted) | -$0.62 | -$2.64 | -$10.63 | $0.03 |
| Operating cash flow | -$85.81M | -$9.96M | -$13.39M | $2.06M |
| Free cash flow | -$85.97M | -$10.07M | -$13.39M | $1.87M |
| Cash & equivalents | $15.48M | $8.70M | $1.95M | $3.62M |
| Total assets | $24.05M | $24.25M | $24.52M | $24.90M |
| Total liabilities | $30.73M | $8.13M | $21.76M | $4.58M |
| Shareholders' equity | -$6.67M | $16.13M | $2.76M | $20.32M |
| Return on year-end equity | n/a | -67.2% | -287.9% | 4.0% |
| Shares outstanding | 90.15M | 3.76M | n/a | 31.06M |
Revenue, most recent five fiscal years
| Fiscal year | Immunic, Inc. | Kiora Pharmaceuticals Inc | HCW Biologics Inc. | Integrated Biopharma Inc |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $54.2K Ended 2025-12-31 | $54.35M Ended 2025-06-30 |
| 1 year earlier | n/a | $16.02M Ended 2024-12-31 | $2.57M Ended 2024-12-31 | $50.32M Ended 2024-06-30 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $2.84M Ended 2023-12-31 | $50.67M Ended 2023-06-30 |
| 3 years earlier | n/a | n/a | $6.72M Ended 2022-12-31 | $56.25M Ended 2022-06-30 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $0 Ended 2021-12-31 | $63.56M Ended 2021-06-30 |